Board of directors

Sean brings extensive experience within oncology, pharmaceutical and medical communication to his non-executive role at Everything Genetic. A strategic thinker, business leader, mentor and successful entrepreneur, Sean is commercially and financially focused with a natural ability to understand what makes companies tick.

He brings practical and strategic knowledge to help the company generate more revenue, maximise margins and increase operational efficiency.

Ranjit is Professor at Wolfson Institute of Population Health, Queen Mary University of London, and Consultant Gynaecological Oncologist at Barts and the Royal London Hospital. He led the research on the PROMISE Pilot study, a population-risk prediction and stratification for targeting ovarian cancer and was involved in the RRESDO study for cancer diagnostics.

Manchanda is co-Lead for the Cancer Prevention Theme at the Barts CRUK Cancer Centre, and appointed as Speciality Research Lead for Gynaecological Cancer, NIHR North Thames Clinical Research Network (CRN). He is the Integrated Academic Training Programme Director, London Speciality School of Obstetrics & Gynaecology, Health Education England. He also leads the RCOG Advanced Professional Module (APM) in Clinical Research for North Central and North East London. Currently, he is leading the PROTECT-C and DETECT general population study for cancer risk in women with Yorkshire Cancer Research.

Maurice was a founding partner of the London Oncology Clinic, a private cancer clinic in Harley Street where he pioneered new standards of patient care and treatment.

A highly experienced Board Chair and charity trustee with an extensive record in driving organisational growth, transforming patient experience, and establishing best-practice governance and risk management for medical institutions.

Professor Evans has established a national and international reputation in clinical and research aspects of cancer genetics, having developed a nationally regarded clinical service for cancer genetics in the North West.

He is a Consultant at the Central Manchester Hospitals NHS Foundation Trust, The Christie NHS Foundation Trust and is a lead clinician on the NICE familial breast cancer guideline group and a Trustee of BCN and the Neuro Foundation.

Professor Evans also serves as Chief Investigator on two NIHR program grants (2009-2014, £1.59 million) (2017-2020, £1million) on breast cancer risk prediction and has an NIHR RfPB grant as CI (2011).